Verona Pharma declares positive Phase 2 data of ensifentrine in COPD
Category: #health  By Pankaj Singh  Date: 2019-08-06
  • sharesocial_share_icon
  • Twitter
  • Facebook
  • LinkedIn

Verona Pharma declares positive Phase 2 data of ensifentrine in COPD
  • The company announces positive results of ensifentrine for the treatment of chronic obstructive pulmonary disease.
  • Primary and secondary lung function end-points were met successfully in the Phase 2 trial of the dry powder inhaler.

United Kingdom based-Verona Pharma plc reportedly posted positive Phase 2 results of ensifentrine for the management of chronic obstructive pulmonary disease. The sources reported that the data also included the results met by the primary and secondary lung function points during the Phase 2 trial.

As per authentic sources, the trial highlighted the results achieved for primary as well secondary endpoints. The primary points portrayed statistical and clinical dose-dependent advancement in lung function whereas the secondary points focussed upon data support of daily dosing where ensifentrine was able tolerate all the levels. 

Reportedly, the primary endpoint met a peak of FEV11  that represented improvements over baseline of 102 mL for the 150 µg2 dose, 175 mL for the 500 µg dose, 180 mL for the 1500 µg dose and so on. The secondary endpoints met major advances in FEV11  which were observed for over 12 hours for 7 days.

Jan-Anders Karlsson, Chief Executive Officer of Verona Pharma was reportedly quoted stating that the results obtained with the DPI formulation support the company’s view about ensifentrine being an effective bronchodilator for the COPD patients. The company’s Dpi formulation has been claimed to be adapted to different DPI devices used globally. It further plans to conclude the development and commercialization of the formulation with an alliance, Karlsson added.

Joseph A Boscia, Pulmonary Physician and Principle Investigator at Vitalink Research Union was quoted stating that the magnitude of response achieved by the Phase 2 trial for COPD patients is commendable. The result highlights the possibility of ensifentrine’s mechanism to help in lung function improvement and an urgent need for developed treatment.

For the records, Verona Pharma plc focuses upon the expansion and commercialization of novel medications for the treatment of respiratory diseases with major unattended medical needs.

Source credit: https://www.globenewswire.com/news-release/2019/08/05/1896642/0/en/Verona-Pharma-Reports-Positive-Phase-2-Results-with-Dry-Powder-Inhaler-Formulation-of-Ensifentrine-in-COPD.html



About Author

Pankaj Singh

Email: [email protected]   linkdin twitter

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

More News By Pankaj Singh

Debenhams announces plans to close its remaining shops on 15th May

Debenhams announces plans to close its remaining shops on 15th May

By Pankaj Singh

Debenhams, a department store company, has reportedly announced the closure of its remaining 49 stores by 15th May, shutting more than 200 years of trade on the UK high streets.

Tricol enters sales & marketing agency agreement with NorthStar

Tricol enters sales & marketing agency agreement with NorthStar

By Pankaj Singh

Tricol Biomedical, a fully integrated medical devices company, has recently announced a sales & marketing agency agreement with NorthStar Sales Alliance for its hemostatic products. The deal will take immediate eff...

T-ROC unites with Conversity to enhance online shopping experience

T-ROC unites with Conversity to enhance online shopping experience

By Pankaj Singh

The Revenue Optimization Companies (T-ROC) has reportedly announced its partnership with Conversity, the IGS (Intelligent Guided Selling) platform creator. This partnership was entered in a bid to enhance the in-store ...